Author

M. See

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Assay:Hi-C· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Barugahare· 1 shared A. E. Morey· 1 shared A. Kallies· 1 shared A. Salavaty· 1 shared A. W. Goldrath· 1 shared B. E. Russ· 1 shared B. Yu· 1 shared C. Mackenzie-Kludas· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Barugahare

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Active maintenance of CD8+ T cell naivety through regulation of global genome architecture

B. E. Russ, K. Tsyganov, S. Quon, B. Yu, J. Li, J. K. Lee, M. Olshansky, Z. He, P. F. Harrison, A. Barugahare, M. See, S. Nuessing, A. E. Morey, V. A. Udupa, T. J. Bennett, , S. J. Turner

This study shows that transcription factors maintain CD8+ T cell naivety by enforcing a distinct chromatin architecture that remodels upon activation.

bioRxiv · Feb 26, 2023 · PreprintImmunology

Parallel use of pluripotent human stem cell lung and heart models provide new insights for treatment of SARS-CoV-2

R. Rudraraju, M. J. Gartner, J. A. Neil, E. S. Stout, J. Chen, E. J. Needham, M. See, C. Mackenzie-Kludas, L. Y. Yang, M. Wang, H. Pointer, K. Karavendzas, D. Abu-Bonsrah, D. Drew, Y. B. Y. Sun, , K. Subbarao

The paper uses human pluripotent stem cell-derived lung and heart models to identify antiviral compounds with distinct profiles, highlighting the need for multi-organ testing in SARS-CoV-2 treatment.

bioRxiv · Sep 20, 2022 · PreprintMicrobiology